Propofol during Cardiopulmonary Bypass in a Patient Susceptible to Malignant Hyperpyrexia

Byrick RJ , Rose DK , Ranganathan N. Management of a malignant hyperthermia patient during cardiopulmonary bypass. Can Anaesth Soc J 1982; 29:50–54.

Gronert GA. Malignant hyperthermia. Anesthesiology 1980; 53:395–423.

MacGullivray RG , Jann H , Vanker E , Gemmel L , Mahomedy AE. Development of malignant hyperthermia obscurred by cardiopulmonary bypass. Can Anaesth Soc J 1986; 29:50–54.

Hurst JW , King SB , Walters PF , Friesinger GC , Edwards JE. Atherosclerotic coronary heart disease: angina pectoris, myocardial infarction and other manifestations of myocardial ischaemia. In: Hurst JW , ed. The Heart, 5th ed. McGraw-Hill, New York 1982; 1095–1096.

Richardson J. Propofol infusion for coronary artery bypass surgery in a patient with suspected malignant hyperpyrexia. Anaesthesia 1987; 42:1125.

Denborough MA , Forster JFA , Lovell RRH , Maplestone PA , Villiers JD. Anaesthetic deaths in a family. Br Med J 1962; 34:395–396.

Ellis FR , Halsall PJ , Harriman DGF. The work of the Leeds Malignant Hyperpyrexia Unit, 1971–84. Anaesthesia 1986; 41:809–815.

Gronert GA. Malignant Hyperthermia. In: Miller RD , ed. Anaesthesia, 2nd ed. Churchill Livingstone, New York 1986; 1971–1994.

Ording H. Diagnosis of susceptibility to malignant hyperthermia in man. Br J Anaesth 1988; 60:287–302.

The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br Med J 1984; 56:1267–1269.

Hefron JJA. Malignant hyperthermia: Biochemical aspects of the acute episode. Br J Anaesth 1988: 60:274–278.

Stark RD , Binks SM , Dutka VN , O'Connor KM , Arnstein MJA , Glen JB. A review of the safety and tolerance of propofol, Postgrad Med J 1985; 60, suppl. 3:152–156.

Robertson WR , Reader SCJ , Davison R et al. On the biopotency and site of action of drugs affecting endocrine tissues, with special reference to the anti-steroidogenic effect of anaesthetic agents. Postgrad Med J 1985; 61. suppl. 3:145–151.

Denborough M , Hopkinson KC. Propofol and malignant hyperpyrexia. Lancet 1988; i:191.

Verburgh MP , de Grood PRRM. Safety of propofol in malignant hyperthermia. Preliminary results. Anaesthesia 1988: 43, suppl: 121.

de Grood PRRM , Ruys AHC , van Egmond J , Booij LHDJ , Crul JF. Propofol emulsion for total intravenous anaesthesia. Postgrad Med J 1985; 61. suppl 3:65–69.

Grounds RM , Lalor JM , Lumley J , Royston D , Morgan M. Propofol infusion for sedation in the Intensive Care Unit: preliminary report. Br Med J 1987; 294:397–400.

Patrick MR , Blair IJ , Feneck RO , Sevel PS. A comparison of the haemodynamic effects of propofol and thiopentone in patients with coronary artery disease. Postgrad Med J 1985; 61, suppl 3:23–27.

Gepts E , Claeys AM , Camu F. Pharmacokinetics of propofol administered by continuous intravenous infusion in man. Postgrad Med J 1985; 61, suppl 3:51–52.

Cockshott ID. Propofol pharmacokinetics and metabolism — an overview. Postgrad Med J 1985; 61, suppl 3:45–50.

Kay NH , Sear JW , Uppington J , Cockshott ID , Douglas EJ. Disposition of propofol in patients undergoing surgery. Br J Anaesth 1986; 58:1075–1079.

Ehler WJ , Mack JW , Brown DL , Davis RF. Avoidance of malignant hyperthermia in a porcine model for experimental open heart surgery. Lab Anim Soc 1985: 35:172–175.

Britt BA. Dantrolene. Can Anaesth Soc J 1984; 31:61–75.

Ward A , Chaggman MO , Sorkin EM. Dantrolene. A review of its pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spacticity. Drugs 1986; 32:130–168.

Harrison GG. Dantrolene — dynamics and kinetics. Br J Anaesth 1988; 60:279–286.

Ruhland G , Hindle AJ. Malignant hyperthermia after oral and intravenous pre-treatment with dantrolene in a patient susceptible to malignant hyperthermia. Anesthesiology 1984; 60:159–160.

Fitzgibbons DC. Malignant hyperthermia following pre-operative oral administration of dantrolene. Anesthesiology 1981; 54:73–75.